Non-Hodgkin Lymphoma

Ibrutinib given prior to apheresis was associated with improved outcomes with tisagenlecleucel vs postapheresis administration in relapsed/refractory LBCL.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in March 2026 spanning tumor types.

Glofitamab combined with CAR T-cell therapy is associated with improved outcomes in relapsed/refractory B-cell lymphoma.

Updated data from TRANSCEND FL showed durable efficacy outcomes with liso-cel in relapsed/refractory follicular lymphoma.

Tafasitamab has been approved by ANVISA for the treatment of relapsed or refractory follicular lymphoma.

Retrospective data showed longer durations of bridging therapy with a BTK inhibitor improved CAR T-cell therapy response in relapsed/refractory DLBCL.

A drug withdrawal in follicular lymphoma and epithelioid sarcoma, a CRL in lung cancer, and priority review in breast cancer highlight this week's top oncology news.

The FDA indications for tazemetostat in relapsed/refractory follicular lymphoma and epithelioid sarcoma are being voluntarily withdrawn.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in February 2026 spanning tumor types.

The top 5 OncLive TV videos of the week cover insights in genitourinary cancers, hematologic malignancies, colorectal cancer, and sarcoma.

The FDA approved a frontline acalabrutinib regimen in CLL/SLL and a simplified dosing schedule for Rybrevant Faspro in EGFR+ NSCLC and will review NDAs in PCNSL and breast cancer.

An NDA for tirabrutinib in relapsed or refractory primary central nervous system lymphoma has been accepted for review by the FDA.

At The University of Texas MD Anderson Cancer Center, research breakthroughs are made through collaboration between leading clinicians and scientists.

OncLive heard from experts across oncology specialties about the biggest updates from the 2026 Transplantation and Cellular Therapy Meetings.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in January 2025 spanning tumor types.

The top 5 OncLive TV videos of the week cover insights in acute lymphoblastic leukemia, breast cancer, urothelial cancer, ovarian cancer, and follicular lymphoma.

Nathan Denlinger, DO, discusses real-world data with second-line liso-cel and axi-cel in patients with relapsed/refractory large B-cell lymphoma.

Fernando Gibran-Nunes, MD, highlights findings from a meta-analysis investigating the efficacy and safety of loncastuximab tesirine in pretreated DLBCL.

The FDA granted priority review to Dato-DXd in triple-negative breast cancer, accepted an NDA for zanzalintinib plus atezolizumab in mCRC, and more.

The FDA updated axi-cel labeling to remove the limitation of use for patients with relapsed or refractory primary central nervous system lymphoma.

Ahead of the 2026 Transplantation & Cellular Therapy Meetings, experts preview data on CAR T-cell therapy efficacy, donor access, and toxicity mitigation.

The FDA has approved Darzalex Faspro plus VRd for select multiple myeloma and several applications are under regulatory review in lung and GI cancers.

Dr Phillips discusses updated data from the EPCORE NHL-1 trial investigating epcoritamab monotherapy in patients with relapsed/refractory LBCL.

Sofi-cel has received FDA breakthrough therapy designation for heavily pretreated patients with relapsed/refractory T-ALL and T-LBL.

Epcoritamab displayed a significant PFS benefit vs chemotherapy in relapsed/refractory DLBCL.